

SHORT COMMUNICATION

Axial spondylometaphyseal dysplasia is also caused by *NEK1* mutations

Zheng Wang^{1,2,8}, Eva Horemuzova^{3,8}, Aritoshi Iida¹, Long Guo¹, Ying Liu⁴, Naomichi Matsumoto⁵, Gen Nishimura⁶, Ann Nordgren⁷, Noriko Miyake⁵, Emma Tham⁷, Giedre Grigelioniene⁷ and Shiro Ikegawa¹

Axial spondylometaphyseal dysplasia (axial SMD) is a unique form of SMD characterized by dysplasia of axial skeleton and retinal dystrophy. Recently, *C21orf2* has been identified as the first disease gene for axial SMD; however, the presence of genetic heterogeneity is known. In this study, we identified *NEK1* as the second disease gene for axial SMD. By whole-exome sequencing in a patient with axial SMD, we identified compound heterozygous mutations of *NEK1*, c.3107C>G (p.S1036*) and c.3830A>C (p.D1277A), which co-segregated in the family. *NEK1* mutations have previously been found in three types of short rib thoracic dystrophy, which have no retinal dystrophy. The skeletal phenotype of our patient was milder than those of previously reported cases with *NEK1* mutations and those with axial SMD harboring *C21orf2* mutations. Phenotypes associated with *NEK1* mutations are variable and the phenotype–genotype correlation in skeletal ciliopathies is challenging.

Journal of Human Genetics (2017) 62, 503–506; doi:10.1038/jhg.2016.157; published online 26 January 2017

Spondylometaphyseal dysplasia (SMD) is a group of genetic skeletal disorders that show abnormal development of spine and metaphyses of long tubular bones.¹ Axial SMD (MIM 602271) is a subtype of SMD. The main clinical features of axial SMD include (1) mild postnatal growth failure, (2) severe chest deformity and (3) impaired visual acuity with retinal dystrophy.^{2–4} The radiological features of axial SMD include (1) cupped and flared anterior ends of ribs, (2) lacy ilia and (3) metaphyseal dysplasia of proximal femora with irregular and enchondroma-like metaphyses.⁵

Recently, *C21orf2* was identified as the disease gene for axial SMD; however, evidence indicating for genetic heterogeneity of axial SMD was also found.⁵ In this study, we have identified *NEK1* as the second disease gene for axial SMD.

The study was approved by the Ethics Committees in RIKEN Center for Integrative Medical Sciences and Karolinska Institutet. The proband was the second child of a non-consanguineous Caucasian couple. The auxology data of the family is presented in Supplementary Table S1. He was considered to be healthy until 7 years of age, when his vision deteriorated abruptly. He was diagnosed with hypermetropia, astigmatism and neuroretinal degeneration. Electroretinogram (ERG) at age 11 years showed severe retinal dystrophy (Figure 1a). The skeletal dysplasia was found at an age of 8 years. He had a slim

thoracic cage and hyperflexible finger joints. He did not have short stature, facial abnormalities, cleft lip and/or palate, and dysplasia of fingers. Skeletal survey showed a narrow and long thorax, mild platyspondyly with rounded vertebral bodies, underdeveloped lower part of the pelvis, sclerotic proximal femoral metaphyses and mild metaphyseal broadening of the distal femora and proximal tibia (Figure 1b–f). Echocardiography revealed mild insufficiency of bicuspid and tricuspid valves. Laboratory tests including liver and kidney evaluation were normal. On basis of the clinical and radiological grounds mentioned above, a diagnosis of axial SMD was made.

Genomic DNA was extracted from peripheral blood of the patient and his family members (Supplementary Figure S1A). Initially, the coding exons and surrounding intronic regions of *C21orf2* were examined by Sanger sequencing as described previously,⁵ but no candidate variant was found in *C21orf2*. Then whole-exome sequencing on the patient's DNA was performed as described previously.^{5,6} The summary of the sequencing performance is provided in Supplementary Table S2. By using autosomal recessive model and filtering strategy described previously,⁵ we detected two variants in the gene *NEK1*. *NEK1* (NM_001199397) consists of 36 exons and encodes a protein of 1286 amino acids. Four other splicing isoforms with minor in-frame alterations (NM_012224, NM_001199398–400) are

¹Laboratory of Bone and Joint Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan; ²Department of Medical Genetics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; ³Department of Women's and Children's Health, Karolinska Institutet and Department of Pediatric Endocrinology, Karolinska University Hospital, Stockholm, Sweden; ⁴Department of Clinical Neurophysiology, Karolinska University Hospital Huddinge and Department of Ophthalmology, The South Hospital, Stockholm, Sweden; ⁵Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan; ⁶Department of Pediatric Imaging, Tokyo Metropolitan Children's Medical Center, Fuchu, Japan and ⁷Department of Clinical Genetics and Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

⁸These authors contributed equally to this work.

Correspondence: Dr G Grigelioniene, Department of Clinical Genetics and Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm 17176, Sweden.

E-mail: Giedre.Grigelioniene@ki.se

or Professor S Ikegawa, Laboratory for Bone and Joint Diseases, Center for Integrative Medical Sciences, RIKEN, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

E-mail: sikegawa@ims.u-tokyo.ac.jp

Received 28 October 2016; revised 21 November 2016; accepted 23 November 2016; published online 26 January 2017




Figure 1 Clinical features of the patient. (a) Electroretinogram of the patient at age 11 years. Rod response, mixed rod-cone response, single cone response and 30 Hz flicker cone response of a normal subject (left) and the patient (right). The patient showed extremely diminished mixed rod-cone response with non-recordable rod response, oscillatory potentials and cone responses, indicating a widespread retinal degeneration. (b–f) Radiographs of the patient at age 8 years. (b) Chest A-P. Narrow thorax with short ribs. (c) Lateral spine. Mild platyspondyly with rounded, dorsally wedged vertebral bodies. (d) Lower leg A-P. Mild metaphyseal broadening of the proximal tibia. (e) Hip A-P. Short ilia with narrow greater sciatic notches and horizontal acetabula, mildly flat capital femoral epiphyses, and irregular trabeculae in both femoral necks. (f) Hand A-P. Mild shortening of the 4th and 5th metacarpals.




Figure 2 Domain structure of NEK1 protein and distribution of mutations. The amino acid sequence of NEK1 protein refers to NP_001186326. S_TKc: serine/threonine kinase catalytic domain. Grey box: coiled-coil region; black box: low-complexity region. Dot-line arrow: deleterious mutations (nonsense mutation, splicing mutation, insertion or deletion that causes frame-shift); solid-line arrow: missense mutation. Mutations identified in the present study are in bold. Splicing mutations are in bracket and are displayed on the DNA level. A large deletion described in mouse PKD model is not included in this figure since its detailed position is not available.

Table 1 NEK1 mutations in human and mouse diseases

Mutation ^a			Mode of inheritance	Phenotype	Reference
Nucleotide	Protein	Position			
c.379C>T	p.R127*	Exon 6	AR	SRTD6	14
(c.313-1A>G) ^b	(p.S104fs)	Intron 6	AR	SRTD3	21
c.420_421insG ^c	p.T141Dfs*11	Exon 7	AR	PKD (mouse model, <i>kat</i> ^{2J})	22
c.433G>A	p.G145R	Exon 7	AR	SRTD6	16
c.514C>T	p.P172S	Exon 8	AR	SRTD1/CED1	17
c.552-1G>A	p.S184fs	Intron 8	AR	SRTD6	15
c.758T>C	p.L253S	Exon 10	AR	SRTD6	16
c.869-2A>G	p.A290fs	Intron 11	AR	SRTD6	14
c.869-1G>T	p.A290fs	Intron 11	AR	SRTD1/CED1	17
c.1640dupA	p.N547Kfs*2	Exon 19	AR	SRTD6	14
c.2931delTinsGG	p.D977Efs*6	Exon 30	AR	SRTD6	16
c.3107C>G	p.S1036*	Exon 31	AR	Axial SMD	This study
c.3830A>C	p.D1277A	Exon 35	AR	Axial SMD	This study
Large deletion ^d	NA	NA	AR	PKD (mouse model, <i>kat</i>)	22

Abbreviations: AR, autosomal recessive; Axial SMD, axial spondylometaphyseal dysplasia; CED1, cranioectodermal dysplasia 1; NA, not available; PKD, polycystic kidney disease; SRTD, short-rib thoracic dysplasia (with or without polydactyly).

SRTD3: OMIM #613091; previous Verma-Naumoff syndrome.

SRTD6: OMIM #263520; previous short rib-polydactyly syndrome, Majewski type.

SRTD1: OMIM %208500; previous Jeune asphyxiating thoracic dystrophy (JATD).

CED1: OMIM: #218330; previous Sensenbrenner syndrome.

Axial SMD: OMIM 602271.

^aAll previously reported mutations were converted to the corresponding positions in NM_001199397.1 and NP_001186326.

^bThe indexed 'splicing mutation' is actually a normal splicing acceptor sequence (NM_001199397.1).

^cMouse *NeK1* mutations were converted to the corresponding positions in NM_001199397 and NP_001186326 in hg19 (see text for details).

^dInformation on the accurate position of this deletion is not available.

known. The detected *NEK1* mutations are c.3107C>G (p.S1036*) in exon 31 and c.3830A>C (p.D1277A) in exon 35, respectively (numbered according to NM_001199397 and NP_001186326). Sanger sequencing of family members confirmed the exome-sequencing results and showed the segregation of the two variants (Supplementary Figure S1). The variants were very rare in the general population, and were predicted as disease causing by SIFT⁷, PolyPhen2⁸ and MutationTaster⁹ (Supplementary Table S3).

NEK1 (OMIM: 604588) belongs to the NIMA (never in mitosis gene a)-related kinase family, which is conserved in evolution⁹ and involved in multiple cellular process, including mitosis, DNA repair, microtubule dynamics and ciliogenesis.^{10,11} A recent siRNA-based functional genomics screening has revealed that *NEK1* forms a functional module of ciliogenesis along with *C21orf2* and *SPATA7*.¹² *C21orf2* is the known disease-causing gene of axial SMD.⁵

At present, 11 *NEK1* mutations related to human or mouse monogenic phenotypes were reported (Table 1, Figure 2). Previous

NEK1 mutations were reported in various transcripts in human and mouse. We therefore unified human *NEK1* mutations and mouse *Nek1* mutation in *Kat*^{2J} in reference to human transcript NM_001199397 and NP_001186326 (hg19) by using NCBI BLAST and Clustal X version 2.0.¹³ The *NEK1*-related phenotypes were described according to the latest version of nosology and classification guide of genetic skeletal disorders.¹ Seven *NEK1* mutations are reported in short-rib thoracic dysplasia 6 (SRTD6; OMIM #263520), a skeletal disease more severe than axial SMD. SRTD6 is characterized by short ribs and limbs, median cleft lip, pre- and post-axial polysyndactyly, genital abnormalities, anomalies of epiglottis and viscera, but has no retinal dystrophy.^{14–16} A 3-year-old patient who is a compound heterozygote for *NEK1* mutations has a phenotype overlapping with SRTD1 (OMIM %208500) and cranioectodermal dysplasia 1 (OMIM #218330 CED1), but also without retinal dystrophy.¹⁷ Two autosomal recessive mouse strains generated for polycystic kidney disease (PKD), *kat* and *kat*^{2J}, have *Nek1*

mutations. Besides the PKD phenotype, skeletal changes of these mice only include decreased body size and abnormal craniofacial morphology.¹⁸

The phenotypic variability could be explained by the location of mutations on the NEK1 protein. Most of the previous mutations are in the N-terminal of the protein, in or near the serine/threonine kinase catalytic domain of this enzyme (Figure 2). The two mutations identified in this study were located in the C-terminal and probably have milder alteration of protein structure and function.

Wheway *et al.*¹² proposed that disruption of SPATA7-C21orf2 interaction contributes to the retinal phenotype, while disruption of NEK1-C21orf2 interaction contributes to the skeletal phenotype. However, the effect of NEK1 mutations in the visual system has been unrecognizable because all affected patients and mouse strains suffered from perinatal death due to thoracic hypoplasia. Here we provide the first *in vivo* evidence that NEK1 mutation could cause a retinal phenotype in patients with mild skeletal dysplasia. The similarity of the phenotype observed in this patient with NEK1 mutations and previously described patients with C21orf2 mutations provided additional *in vivo* evidence for the potential interaction of NEK1 and C21orf2.

The severity of skeletal phenotypes in axial SMD is variable.⁵ It was reported that axial SMD patients with the same C21orf2 bi-allelic mutation showed broad phenotype variability.^{3,5} Regarding the radiographic phenotype of axial SMD, the patient is at the mildest end of the phenotype spectrum. In contrast to previous axial SMD cases, which show moderate-to-severe short stature becoming manifest in early childhood,⁵ the patient's height followed approximately -1 SD since birth. Our findings are consistent with known phenotype variability characteristic for skeletal ciliopathies.^{19,20}

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the family for participating in the study. This study is supported by KAKENHI Grant-in-Aid for Scientific Research (B) (NMI, No 25293235), Takeda Science Foundation (ZW), and research grants from Japan Agency For Medical Research and Development (AMED) (SI, NMA, No 16k0109068h0003). This study is also supported by the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet and by grants from Kronprinsessan Lovisas, Stiftelsen Frimurare Barnhuset in Stockholm, Hjärfonden, Axel Tielmans Minnesfond, Samariten and Promobilia Foundations (GG, AN).

- Bonafe, L., Cormier-Daire, V., Hall, C., Lachman, R., Mortier, G., Mundlos, S. *et al.* Nosology and classification of genetic skeletal disorders: 2015 revision. *Am. J. Med. Genet. A* **167A**, 2869–2892 (2015).
- Ehara, S., Kim, O.H., Maisawa, S., Takasago, Y. & Nishimura, G. Axial spondylometaphyseal dysplasia. *Eur. J. Pediatr.* **156**, 627–630 (1997).
- Isidor, B., Baron, S., Khau van Kien, P., Bertrand, A. M., David, A. *et al.* Axial spondylometaphyseal dysplasia: confirmation and further delineation of a new SMD with retinal dystrophy. *Am. J. Med. Genet. A* **152A**, 1550–1554 (2010).
- Suzuki, S., Kim, O. H., Makita, Y., Saito, T., Lim, G. Y., Cho, T. J. *et al.* Axial spondylometaphyseal dysplasia: additional reports. *Am. J. Med. Genet. A* **155A**, 2521–2528 (2011).
- Wang, Z., Iida, A., Miyake, N., Nishiguchi, K.M., Fujita, K., Nakazawa, T. *et al.* Axial spondylometaphyseal dysplasia is caused by C21orf2 mutations. *PLoS ONE* **11**, e0150555 (2016).
- Guo, L., Girisha, K. M., Iida, A., Hebbar, M., Shukla, A., Shah, H. *et al.* Identification of a novel LRRK1 mutation in a family with osteosclerotic metaphyseal dysplasia. *J. Hum. Genet.* **62**, 437–441 (2017).
- Kumar, P., Henikoff, S., Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.* **4**, 1073–1081 (2009).
- Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P. *et al.* A method and server for predicting damaging missense mutations. *Nat. Methods* **7**, 248–249 (2010).
- Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nat. Methods* **11**, 361–362 (2014).
- Fry, A. M., O'Regan, L., Sabir, S. R. & Bayliss, R. Cell cycle regulation by the NEK family of protein kinases. *J. Cell Sci.* **125**, 4423–4433 (2012).
- Kim, G., Kim, J. Y. & Choi, H. S. Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 as a therapeutic target in hepatocellular carcinoma. *Biol. Pharm. Bull.* **38**, 975–979 (2015).
- Wheway, G., Schmidts, M., Mans, D. A., Szymanska, K., Nguyen, T. M., Racher, H. *et al.* An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. *Nat. Cell Biol.* **17**, 1074–1087 (2015).
- Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H. *et al.* Clustal W and Clustal X version 2.0. *Bioinformatics* **23**, 2947–2948 (2007).
- Thiel, C., Kessler, K., Giessel, A., Dimmler, A., Shalev, S. A., Beinder, E. *et al.* NEK1 mutations cause short-rib polydactyly syndrome type Majewski. *Am. J. Hum. Genet.* **88**, 106–114 (2011).
- Chen, C. P., Chang, T. Y., Chen, C. Y., Wang, T. Y., Tsai, F. J., Wu, P. C. *et al.* Short rib-polydactyly syndrome type II (Majewski): prenatal diagnosis, perinatal imaging findings and molecular analysis of the NEK1 gene. *Taiwan J. Obstet. Gynecol.* **51**, 100–105 (2012).
- El Hokayem, J., Huber, C., Couvé, A., Aziza, J., Baujat, G., Bouvier, R. *et al.* NEK1 and DYNC2H1 are both involved in short rib polydactyly Majewski type but not in Beemer Langer cases. *J. Med. Genet.* **49**, 227–233 (2012).
- McInerney-Leo, A. M., Harris, J. E., Leo, P. J., Marshall, M. S., Gardiner, B., Kinning, E. *et al.* Whole exome sequencing is an efficient, sensitive and specific method for determining the genetic cause of short-rib thoracic dystrophies. *Clin. Genet.* **88**, 550–557 (2015).
- Vogler, C., Homan, S., Pung, A., Thorpe, C., Barker, J., Birkenmeier, E. H. *et al.* Clinical and pathologic findings in two new allelic murine models of polycystic kidney disease. *J. Am. Soc. Nephrol.* **10**, 2534–2539 (1999).
- Huber, C. & Cormier-Daire, V. Ciliary disorder of the skeleton. *Am. J. Med. Genet. C* **160C**, 165–174 (2012).
- Geister, K. A. & Camper, S. A. Advances in skeletal dysplasia genetics. *Annu. Rev. Genomics Hum. Genet.* **16**, 199–227 (2015).
- Chen, C. P., Chern, S. R., Chang, T. Y., Su, Y. N., Chen, Y. Y., Su, J. W. *et al.* Prenatal diagnosis and molecular genetic analysis of short rib-polydactyly syndrome type III (Verma-Naumoff) in a second-trimester fetus with a homozygous splice site mutation in intron 4 in the NEK1 gene. *Taiwan J. Obstet. Gynecol.* **51**, 266–270 (2012).
- Upadhyay, P., Birkenmeier, E. H., Birkenmeier, C. S. & Barker, J. E. Mutations in a NIMA-related kinase gene, Nek1, cause pleiotropic effects including a progressive polycystic kidney disease in mice. *Proc. Natl. Acad. Sci. U S A.* **97**, 217–221 (2000).

Supplementary Information accompanies the paper on Journal of Human Genetics website (<http://www.nature.com/jhg>)